Home Blog Page 1339

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

By
Advertorial Desk
-

BEIJING, Jan. 20, 2026 /PRNewswire/ — LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held on February 12, 2026 at 11 a.m. (Beijing time) at Unit 1301, Tower 1, China Central Place, No. 81 Jianguo Road, Chaoyang District, Beijing, People’s Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced Agreement and Plan of Merger (the “Merger Agreement”) dated November 4, 2025 by and between the Company, Oceanpine Skyline Inc. (“Parent”) and Oceanpine Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Parent, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”) and the transactions contemplated thereby, including the merger.

Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the merger, Merger Sub will be merged with and into the Company and cease to exist, with the Company being the surviving company and becoming a wholly owned subsidiary of Parent. If consummated, the merger will result in the Company becoming a privately held company, and its ordinary shares, par value US$0.0002 each (each, a “Share”), and the warrants to purchase Shares (the “Company Warrants”) will no longer be listed for quotation on any public market place or quotation system, including OTC Pink tier of the OTC Markets. In addition, the Company’s Shares and Company Warrants will cease to be registered under Section 12 of the Securities Exchange Act of 1934 following the consummation of the merger.

The Company’s board of directors, acting upon the unanimous recommendation of a special committee of independent directors established by the board of directors, authorized and approved the execution, delivery and performance of the Merger Agreement, the Plan of Merger and the consummation of the transactions contemplated thereby, and resolved to recommend that the Company’s shareholders vote FOR, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger, and the consummation of the transactions contemplated thereby, including the merger.

Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 will be entitled to attend and vote at the EGM and any adjournment thereof.

Additional information regarding the EGM and the Merger Agreement can be found in the transaction statement on Schedule 13E-3 and the definitive proxy statement attached as Exhibit (a)-(1) thereto, as amended, filed with the U.S. Securities and Exchange Commission (the “SEC”), which can be obtained, along with other filings containing information about the Company, the proposed merger and related matters, without charge, from the SEC’s website (http://www.sec.gov). Requests for additional copies of the definitive proxy statement should be directed to the Company’s Investor Relations Department by phone at +86 (10) 8920-2086 or by email at ir@lakeshorebio.com.

SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies is set forth in the Schedule 13E-3 transaction statement relating to the proposed merger and the definitive proxy statement attached thereto. Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.

This announcement is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities or a solicitation of any proxy, vote or approval with respect to the proposed transaction or otherwise, nor shall it be a substitute for any proxy statement or other filings that have been or will be made with the SEC.

About LakeShore Biopharma Co., Ltd

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.

For more information, please visit https://investors.lakeshorebio.com/.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s business plans and development, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “future,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. LakeShore Biopharma may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about LakeShore Biopharma’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties as to how the Company’s shareholders will vote at the meeting of shareholders; the possibility that events may arise that result in the termination of the Merger Agreement; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 and the proxy statement filed by the Company; the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations; its ability to provide efficient services and compete effectively; its ability to maintain and enhance the recognition and reputation of its brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor inquiries, please contact:

IR Team
Tel: +86 (10) 8920-2086
Email:  ir@lakeshorebio.com 

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

By
Advertorial Desk
-

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflows

TAICHUNG, Jan. 20, 2026 /PRNewswire/ — SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and item-level traceability. Built on an innovative, patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tracking of injectable drugs continues to drive substantial losses through expired inventory, misplaced medications, and regulatory exposure—particularly for high-value or critical products. As enforcement of the U.S. Drug Supply Chain Security Act (DSCSA) accelerates, dependable, high-accuracy RFID-based medication tracking has become essential to both pharmaceutical manufacturing and hospital operations.

LiquidMate O
LiquidMate O

LiquidMate O is purpose-built to enable scalable, item-level tracking across a broad range of injectable liquid categories that have historically constrained direct-on-vial RFID adoption. Its performance has been independently validated through AXIA Lab–defined test scenarios, using representative liquid formulations and workflow conditions aligned with real clinical practice. Key capabilities include:

  • One label across multiple formulations
    Consistent RFID performance across injectable liquids with varying dielectric properties, eliminating formulation-specific labels and significantly reducing SKU complexity.
  • True direct-on-vial design
    Validated on industry-standard 10 mL glass vials with a compact 62 × 20 mm label engineered for curved, space-constrained pharmaceutical packaging.
  • Proven high-density readability
    Independently validated by AXIA Lab, achieving 100% read performance in dense, multi-vial configurations with full 360-degree omnidirectional readability.

While demand for item-level traceability continues to rise, existing RFID approaches have struggled to balance RF performance, scalability, and operational integration. Conventional direct-on-vial solutions often suffer from inconsistent performance on liquid-filled injectables due to dielectric effects, while flag-style labels, although RF-robust, pose handling, automation, and scalability challenges that limit broader adoption. LiquidMate O eliminates this trade-off by delivering a true direct-on-vial RFID solution with consistent performance across diverse injectable formulations. This enables streamlined labeling operations and improved workflow efficiency from manufacturing through point-of-care. By reducing manual scanning steps and minimizing SKU proliferation, LiquidMate O supports real-time inventory visibility, accurate dispensing, and enhanced patient safety without disrupting existing packaging lines.

“With more than two decades of experience supporting healthcare and industrial RFID applications, we have seen how reliability at the item level directly impacts compliance, efficiency, and patient safety,” said Terry Chiang, CEO of SAG. “LiquidMate O reflects our focus on solving the most technically complex tagging challenges in healthcare and delivering scalable, standards-based traceability solutions that pharmaceutical organizations can deploy with confidence.”

Following extensive engineering development and independent validation, LiquidMate O is now qualified for commercial deployment. Built on SAG’s deep expertise in RFID antenna design, materials science, and healthcare workflow integration, the solution is engineered to meet the stringent performance, regulatory, and scalability requirements of pharmaceutical environments. SAG is initiating structured technical engagements to support evaluation and deployment planning for next-generation item-level traceability initiatives.

About SAG

As an RFID tagging challenge enabler, SAG turns complex concepts into production-ready RFID solutions. Through deep expertise in tailored antenna design, materials science, and self-developed manufacturing systems, SAG delivers reliable RFID connectivity that performs under demanding operational and environmental constraints—enabling organizations to address complex, mission-critical workflow challenges through advanced RFID solutions.

www.sag-rfid.com
info@sag.com.tw 

100-Day Countdown Begins: Preparations for 6th Asian Beach Games Enter Final Stretch

By
Advertorial Desk
-

BEIJING, CHINA – Media OutReach Newswire – 20 January 2026 – The 6th Asian Beach Games will be held in Sanya, Hainan Province, China from April 22 to 30. The State Council Information Office held a press conference on Jan. 12 to mark the 100-day countdown to the Games and provide an update on the preparations.

The scene of the press conference of 100-day countdown to the 6th Asian Beach Games.
The scene of the press conference of 100-day countdown to the 6th Asian Beach Games.

At the press conference, it was announced that the Games would feature 14 sports, 15 disciplines, and 63 events, including established Olympic and Asian Games programs like swimming and sailing, as well as emerging sports such as teqball and beach kabaddi.

The 100-day countdown poster for the 6th Asian Beach Games
The 100-day countdown poster for the 6th Asian Beach Games

Eight competition venues (clusters) have been planned to support the event. Five are located along the Sanya Bay — renowned for its “Coconut Dream Promenade,” one is situated alongside the Sanya River, and two are within the Sanya Sports Center. This layout integrates the coastal beauty with the urban landscape. Construction is well underway as scheduled, and all venues are ready to welcome elite athletes from across the Asian continent.

To ensure service support for the Games, the organizing committee has designated 24 official reception hotels, capable of accommodating over 4,000 athletes and team officials. The catering services feature “dining islands” that offer Chinese cuisine, Western-style meals, and authentic Hainan specialties to satisfy the varied culinary preferences of all participating nations and regions.

According to the press conference, the opening and closing ceremonies will be held at Yasha Park within the Tianya Haijiao Scenic Area. By making the sky a backdrop, the sea a setting, and the beach a stage, both ceremonies will blend the beach sports with Hainan’s unique cultural elements. The performances will incorporate the natural beauty of Tianya Haijiao and the captivating local legend of “Luhuitou,” demonstrating the exchange and mutual learning of Asian civilizations in a multidimensional way.

Notably, the medal design for the Sanya Asian Beach Games was officially unveiled on the day. Titled “Tianya Moment,” the medal design draws inspiration from the classic Song Dynasty verse: “As the bright moon rises over the sea, we share this moment from the ends of the earth.” This poetic symbolism extends Sanya’s warm welcome to friends from across Asia. It is reported that a total of 189 medals (63 gold, 6 silver, and 63 bronze) will be awarded during the Games.

In order to foster the deep integration of culture, sports, and tourism, the organizing committee plans to host interactive experiences to promote Hainan’s intangible cultural heritage, Li and Miao ethnic folk performances, and beach concerts in key places such as the Athletes’ Village and the Yasha Park inside the Tianya Haijiao Scenic Area during the event, immersing global visitors in Hainan’s one-of-a-kind cultural charm.

Hainan is fully prepared to embrace the Games as a valuable link to connect the island’s unique tourism offerings. The premium “Competition & Leisure” round-the-island itineraries will invite athletes and visitors to discover Hainan through the Games, allowing them to be immersed in the island’s stunning natural beauty, the wonders of its tropical rainforests, the rich charm of Li and Miao ethnic cultures, and the excitement of duty-free shopping.

The issuer is solely responsible for the content of this announcement.

Solidion Technology Awarded Its Third Grant From The U.S. Army STTR Program

By
Advertorial Desk
-

Grant Proceeds Will Accelerate Research Into Advanced Fiber-based Electronic Battery Systems

DALLAS, Jan. 20, 2026 /PRNewswire/ — Solidion Technology Inc. (“Solidion” or the “Company”) (Nasdaq: STI), an advanced battery technology solutions provider, was notified by the U.S. Department of War/Army STTR Program that it has been awarded a grant to develop an advanced fiber-based electronic battery system built on a coaxial carbon nanotube (CNT) yarn architecture. This marks the third grant Solidion has received in the last six months.

The Company previously announced that it had received the prestigious 2025 R&D 100 Award in partnership with Oak Ridge National Laboratory (ORNL), for innovation in Electrochemical Graphitization in Molten Salts (E-GRIMS) as well as a grant to advance research and development of Electrochemical Manufacturing of High-Performance Graphite Based on Biomass-Derived Carbon funded by ARPA-E, the Advanced Research Projects Agency, from their highly competitive OPEN program and to scale up the synthesis of a carbon-nanosphere material that will be used as an anti-corrosive additive in molten-salts-based heat transfer fluids for advanced molten salt nuclear reactors.

KEY HIGHLIGHTS OF SOLIDION’S THIRD GOVERNMENT GRANT

  • Collaboration: Research to be conducted jointly with The University of Texas at Dallas
  • Diversification: This innovation is a flexible, rechargeable lithium-ion battery in fiber form: a CNT yarn serves as both the structural core and current collector of the anode, integrated with Solidion’s silicon (Si) as the high-capacity anode material.

Jaymes Winters, Chief Executive Officer of Solidion Technology, stated:

“Advancements in advanced fiber based electronic battery systems are a part of the larger commitment by the Department of War to innovate and collaborate with cutting edge U.S. companies such as Solidion.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 525 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging

By
Advertorial Desk
-

Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more

LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 /PRNewswire/ — 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ™” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.

Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ™ software.
Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ™ software.

CT:VQ™ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”

What the funding enables for hospitals and health systems

4DMedical will use the funding to expand U.S. availability of CT:VQ™ and support health systems with implementation at scale, including:

  • Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
  • Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilization
  • Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio and capabilities in functional lung imaging
  • Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base.

Built to integrate into clinical workflows

4DMedical’s products are delivered through a Software-as-a-Service (SaaS) model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.

Availability

Hospitals and imaging networks interested in evaluating CT:VQ™ can contact 4DMedical for implementation information, workflow considerations, and a demonstration.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical’s software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.

These insights help pulmonologists, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical’s solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.

Photo – https://laotiantimes.com/wp-content/uploads/2026/01/4dmedical_respiratory_imaging.jpg

Monport Laser Launches 2026 Trade-Up Program to Expand Business Laser Engraving Capabilities

By
Advertorial Desk
-

NEW YORK, Jan. 20, 2026 /PRNewswire/ — As businesses face increasing demand for high-quality, precision-engraved products in 2026, modernizing equipment has become essential for staying competitive. To address this, Monport Laser is launching a trade-up program and promotional event from January 19 to February 2, 2026, helping workshops, manufacturers, and creative studios upgrade to advanced laser technology, increase efficiency, and expand production capabilities.

Monport Laser, a global provider of desktop CO2 lasers, fiber laser engravers, and MOPA fiber lasers, delivers professional-grade solutions engineered for speed, precision, and reliability, enabling businesses to meet evolving industry standards and customer expectations.

Trade-Up Program: Level Up Your Laser Engraving Capabilities

The trade-up initiative allows companies to exchange older machines—including lasers, 3D printers, garment printers, welders, or cutters of any brand—for rewards toward new Monport machines. Eligible upgrades include GT Series MOPA fiber laser machines and Effi Series high-speed CO2 laser cutters.

This program empowers businesses to adopt modern technology without workflow disruption, improving operational efficiency and precision. Rewards range up to $700 depending on the machine, helping businesses increase throughput and expand capabilities.

Discover how Monport Laser’s Trade-Up Program can help you upgrade your equipment and expand your workshop capabilities.

GT Series: Advanced Fiber and MOPA Laser Engravers

The GT Series represents Monport’s flagship for advanced fiber laser machines using MOPA technology for metal marking, engineered for precision, speed, and versatility. Key features include:

  • Auto-Focus Technology: Ensures perfect focus on metals such as stainless steel, aluminum, titanium, gold, and silver
  • MOPA Color Marking: Enables vibrant, high-contrast color markings for creative or branding applications
  • Industrial-Grade Galvo Scanners: Support ultra-fine engraving, deep 3D relief, and speeds up to 20,000mm/s
  • Laser Power Options up to 200W: Delivers superior cutting and engraving results for both delicate jewelry and heavy-duty industrial parts
  • Flexible Work Areas: Options from 150×150mm to 200×200mm for small intricate designs or larger industrial applications

The GT Series is ideal for jewelry engraving, industrial parts, custom metalwork, and decorative projects, delivering precise, repeatable results across every application.

Explore the GT Series fiber laser engraver and learn how precision meets productivity.

Effi Series: High-Speed CO2 Laser Cutting and Engraving

The Effi Series offers industrial CO2 laser engravers and cutters designed for versatility, speed, and high-quality results. Key highlights include:

  • Advanced Auto-Focus Technology: Ensures precise engraving on materials of varying thickness
  • Built-in Water Chiller: Maintains optimal operating temperature for sustained productivity
  • High-Power Options: 90W, 100W, 130W, and 150W models accommodate small projects to industrial-scale tasks
  • User-Friendly Design: Compatible with software like LightBurn for intuitive control

The Effi Series CO2 laser engraving machine supports high-speed engraving and cutting across wood, acrylic, leather, fabric, and glass, delivering reliable performance for creative studios and industrial workshops alike.

Discover the Effi Series CO2 laser engraver to enhance versatility and efficiency in your workflow.

Monport Laser Discounts and Free Laser Engraving Accessories

As part of the trade-up program, businesses can also benefit from exclusive savings and complimentary accessories:

  • Discounts: Customers who own an old machine (any brand) receive 8% off all machines on sale, while new customers receive 6% off. 
  • Free Accessories:

    • CO2 Lasers (Reno, Effi, Mega Series): 2 Metal Laser Marking Black Sprays
    • Fiber Lasers (Fiber Series): Fiber Laser Engravers Protective Glasses

These incentives make it easier for businesses to upgrade to desktop CO2 laser engravers, fiber laser engravers, and MOPA fiber lasers while boosting operational efficiency.

Simple, Three-Step Upgrade Process

Monport has designed a streamlined trade-up process:

  1. Apply: Complete a form to select your desired machine upgrade—no return of old equipment required
  2. Receive Reward: Instantly obtain a coupon code for the new machine
  3. Upgrade & Expand: Redeem the reward to acquire GT Series fiber lasers, Effi Series CO2 lasers, or other Monport desktop laser engravers and enhance production capabilities

Learn more about Monport Laser’s Trade-Up Program and how to upgrade your equipment today.

Empowering Innovation and Business Growth

With GT Series MOPA fiber lasers and Effi Series CO2 laser engravers, businesses can increase throughput, expand creative possibilities, and maintain a competitive edge.

Whether marking delicate jewelry, cutting thick materials, or performing deep industrial engraving, Monport Laser engraving machines deliver precision, speed, and reliability—enabling workshops and creative studios to scale operations efficiently.

About Monport Laser

Monport Laser is a global provider of professional-grade laser engraving and cutting solutions, including desktop CO2 lasers, fiber laser engravers, and MOPA fiber lasers. Monport machines are engineered for precision, speed, and reliability, helping businesses modernize workflows, increase productivity, and expand operational capabilities.

Event Duration: January 19 – February 2, 2026

Media Contact:
 Company: Monport Laser
 Email: official@monportlaser.com 
 Website: https://www.monportlaser.com

Hainan FTP’s first month of island-wide special customs operations boosts economic vitality, sets global benchmark

By
Advertorial Desk
-

HAIKOU, CHINA – Media OutReach Newswire – 20 January 2026 – One month into the island-wide special customs operations, the Hainan Free Trade Port (FTP) in south China has maintained smooth and orderly functioning, with initial achievements in logistics efficiency, passenger convenience, and economic aggregation, highlighting the country’s commitment to high-level opening up.

Yangpu Port, the largest cargo port in the Hainan FTP.
Yangpu Port, the largest cargo port in the Hainan FTP.

Hainan Heren Pearl Co., Ltd., which mainly imports pearls from overseas, has emerged as a direct beneficiary of Hainan FTP policies.

Under the value-added processing policy, the company can sell its high-value products to the mainland duty-free, cutting its overall tax burden from about 52 percent to roughly 26 percent and redirecting the savings into research and development, said Zhang Shizhong, the company’s chairman.

“The FTP holds great promise, with more policy dividends set to be released in the future,” Zhang said.

One notable special customs policy is offering “freer access at the first line,” referring to freer trade between Hainan and areas outside China’s customs borders, and “regulated access at the second line,” which involves applying standard customs controls for goods moving from Hainan to the mainland.

According to Haikou Customs, from Dec. 18, 2025 to the early hours of Jan. 18, 2026, the value of “first line” imported zero-tariff goods was 753 million yuan (about 107 million U.S. dollars); the value of processed and value-added goods sold domestically through the “second line” was about 85.9 million yuan.

In Wanning City, production lines at Chia Tai (Hainan) Xinglong Coffee Industry Development Co., Ltd. are running at full capacity. The company imports green coffee beans from Colombia and processes them in Hainan before shipping the finished products to the mainland, enjoying an 8 percent tariff reduction under the FTP policies.

“After the launch of island-wide special customs operations, Hainan will gradually become a value-added processing center and trade hub with global resource allocation capabilities,” said Ye Jian, the company’s general manager. “Enterprises will not only pass through Hainan, but also be able to put down roots here and create higher value.”

Duty-free shopping booms in Hainan FTP.
Duty-free shopping booms in Hainan FTP.

Drawn by the policy incentives, a growing number of companies are choosing to do business in Hainan. The General Administration of Customs said a total of 5,132 new foreign trade enterprises completed registration in Hainan over the past month, an increase in a month roughly equivalent to the total registrations in an entire quarter of 2024.

The total number of registered foreign trade market entities in Hainan has surpassed 100,000, according to official data.

As the policy came into force, major ports across Hainan saw a surge in activity.

Days after Hainan began island-wide special customs operations, a flight from Prague carrying 115 European passengers touched down in the tourist city of Sanya, marking a breakthrough in the high-level opening up of the aviation sector at the Hainan FTP.

The arrival marked the launch of China’s first official passenger route operated under the Seventh Freedom of the Air, which allows foreign carriers to operate flights between two foreign countries without having to land in their home country.

The route is operated by Kazakhstan’s Scat Airlines, with one round-trip scheduled each week.

At Yangpu Port, the largest cargo port in the Hainan FTP, mega-ships berthing in quick succession, gantry cranes operating around the clock, and container trucks moving in tightly coordinated flows have become a routine sight.

“Yangpu will shoulder the role of the main logistics gateway of the Hainan FTP,” said Yang Xiaobin, deputy head of the Transportation, Port and Waterway Bureau of Yangpu Economic Development Zone. “The port aims to build a smart and green international shipping hub and logistics center.”

Container throughput at Yangpu reached 3.31 million twenty-foot equivalent units (TEUs) in 2025, up more than 65 percent from a year earlier.

“It is particularly noteworthy that the Hainan FTP launched island-wide special customs operations at a time of intensifying deglobalization and rising global uncertainty,” said Cui Weijie, deputy director of the Chinese Academy of International Trade and Economic Cooperation, a think tank with the Ministry of Commerce.

“It not only demonstrates China’s unwavering commitment to high-standard opening up, but also injects greater certainty and positive momentum into the global economy and international trade cooperation,” Cui said.

Hashtag: #HainanFreeTradePort #HainanFTP #CustomsReform #FreeTradePort #DutyFreeTrade

The issuer is solely responsible for the content of this announcement.

Noah Holdings’ H1 2026 CIO Report Outlines the Emergence of AI Infrastructure as a Critical Long-Term Asset for Wealth Allocation

By
Advertorial Desk
-

SINGAPORE, Jan. 20, 2026 /PRNewswire/ — Noah Holdings Limited (“Noah” or the “Company”) (NYSE: NOAH and HKEX: 6686), an established wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, today released its H1 2026 CIO Report (“the Report”), titled “Global Wealth Reshaped in the Age of AI: Growth, Allocation, and Legacy.” The Report outlines a fundamental shift in wealth management strategy as AI evolves from a speculative technology theme into a critical, long-term infrastructure asset class.

The Report argues that in an era of persistent macro uncertainty, the core objective of wealth management is shifting from maximizing short-term returns to preserving long-term certainty. Noah’s CIO Office believes that AI has moved beyond the “software-only” phase and entered a long-term infrastructure-building cycle. The primary investment value lies in the physical and operational foundations required for global, large-scale AI deployment — including next-generation data centers, energy systems, smart power grids, and adjacent assets.

“Technological progress does not automatically translate into family-level security,” said Norah Wang, Co-Founder and Chairwoman of Noah Holdings. “True stability for families is not found in short-term market performance, but the ability to preserve direction, dignity, and decision-making capacity across cycles. At Noah, our role is not to predict markets, but to accompany families through structural change with professional judgment, discipline, and long-term vision.”

AI’s growth engine is shifting from innovation at the front end to balance sheets and capital expenditure at the back end. While technology stocks and venture investments remain important, Noah views AI infrastructure as a strategic portfolio anchor, providing structural complementarity — lowering volatility, enhancing cross-cycle stability, and offering long-duration cash flow characteristics.

The CIO Office emphasizes that AI infrastructure does not replace equities, private markets, or venture capital. Instead, it strengthens portfolios by anchoring them in assets tied to long-term global investment in energy and compute capacity. Over the next 10–20 years, rising AI-driven power demand is expected to drive sustained spending across energy systems and digital infrastructure worldwide.

The Report also introduces a three-layer allocation framework for family portfolios, designed to integrate:

  1. Core long-term assets with durable cash flows
  2. Liquidity and risk management layers
  3. Legacy and intergenerational structures to ensure continuity beyond a single market cycle

“The art of true wealth management lies not in amplifying returns in favorable markets, but in helping families preserve direction, dignity, and autonomy across all market conditions,” the Report concludes.

Since 2022, Noah’s CIO Office has published ten CIO reports, forming a consistent and reusable judgment framework for navigating global macro shifts. Previous reports addressed themes such as liquidity reversal, antifragility, bottom-line thinking, balancing short-term security with long-term growth, and technology-driven deflation. The H1 2026 edition continues this tradition by analyzing AI infrastructure as a cornerstone of future asset allocation.

The full Noah Holdings H1 2026 CIO Report is available at: noahmkt.com/42wY.

About Noah Holdings

Noah Holdings Limited (NYSE: NOAH; HKEX: 6686) is an established global wealth management group dedicated to serving Chinese families worldwide. Listed on the New York Stock Exchange in 2010 and dual-listed in Hong Kong, Noah is committed to becoming a long-term, trusted partner for generations of Chinese families. With more than two decades of steady and disciplined development, the Company has built an integrated global service system with four booking centers across mainland China, Hong Kong, Singapore, and the United States.

Guided by a long-term philosophy that “judgment is the foundation of wealth protection,” Noah has developed three professional platforms to support families across different stages of life. ARK Wealth Management provides compliant and coordinated global investment and transaction services; Olive Asset Management focuses on long-term asset allocation and investment management; and Glory Family Heritage specializes in family governance and intergenerational legacy planning. In parallel, Noah’s digital wealth management platform iARK and its AI Relationship Manager “Noya” enhance judgment and real-time service capabilities, enabling clients to make important decisions with greater clarity in complex environments. Through its N+ global ecosystem, Noah also offers clients a long-term community for learning, exchange, and connection—fulfilling its enduring commitment to go beyond wealth and serve with lasting wisdom.

1...1,3381,3391,340...6,568Page 1,339 of 6,568